Pfizer Stock Slips After Report on Vaccine Timing Probe
Pfizer stock slipped about 0.7% to $25.19 after The Wall Street Journal reported on an inquiry looking into the suggestion that the pharmaceutical giant delayed announcing a successful vaccine against Covid-19 until after the election that Trump lost to Biden.
Zacks Investment Research on MSN2d
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?Of late, pharmaceutical behemoth Pfizer Inc.’s PFE stock has struggled, but it remains a bargain with generous dividends. Its ...
We recently published a list of 14 Best Affordable Stocks to Buy According to Hedge Funds. In this article, we are going to ...
China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment' China is stepping up efforts to reassure U.S. corporate giants ...
Pfizer’s PFE stock has risen 5.9% in the past three months. The stock has started to show a consistent increase, with some ups and downs in between, after it took a hammering in the past ...
Pfizer (PFE) stock is lower in Tuesday's session even after the pharmaceutical giant beat top- and bottom-line expectations for its third quarter and raised its full-year outlook. Track all ...
Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback